ACCOUNTING FOR RESIDUAL AMOUNT OF ACTIVE INSULIN IN ARTIFICIAL PANCREAS SYSTEM Russian patent published in 2022 - IPC A61K38/28 A61P3/10 A61M5/31 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the field of systems for control of a blood glucose level, more specifically, to a system for control of a blood glucose level with feedback, such as an artificial pancreas system, which uses a controller using more than one model for accounting for the residual amount of active insulin. A method for accounting for the residual amount of active insulin in a system for measuring a glucose level is described, wherein the system includes a controller. The method contains following stages, which provide for: calculation of the amount of bolus calculated by the system; after calculation of the amount of bolus calculated by the system, administration to a user of the amount of insulin bolus initiated by the user; after administration of the amount of bolus initiated by the user, determination of whether the user has entered a value of blood glucose (hereinafter – BG) concentration into the controller; after determination of whether the user has entered the BG concentration value into the controller, determination of whether the user has entered a value of carbohydrates (hereinafter – CHO) into the controller; if it is determined by the controller that the user entered the BG concentration value into the controller, but did not enter the CHO value, then, the calculation of a component of blood glucose correction for the amount of insulin bolus initiated by the user is carried out based on the BG concentration value, by means of the controller, as follows:

,

where the total amount is the total amount of the amount of insulin bolus initiated by the user, the target value is the target value of the blood glucose level, ISF is a given insulin sensitivity factor, and PFIOB is a value of the patient-oriented residual amount of active insulin; if it is determined that the user did not enter the BG concentration value into the controller, but entered the CHO value, then the calculation, using the controller, of a food component for the amount of insulin bolus initiated by the user is carried out as follows:

max ,

where the total amount is the total amount of the amount of insulin bolus initiated by the user, and CR is a given ratio of grams of carbohydrates and units of insulin; after determination of whether the user has entered BG and CHO concentration values into the controller, then, determination of whether the amount of bolus calculated by the system and the amount of insulin bolus initiated by the user are equal amounts or whether the amount of insulin bolus initiated by the user is the adjusted amount of bolus other than the amount of bolus calculated by the system; and the subsequent use of the controller for the determination of a corrective value of the system-oriented residual amount of active insulin, as corresponding to at least one of the component of blood glucose level correction, the food component, and the adjusted amount of bolus. At the same time, if all of BG concentration value, CHO value, and continuous glucose measurement (CGM) value are not available, then, the calculation of the component of blood glucose correction for the amount of insulin bolus initiated by the user, by means of the controller, is carried out as follows: Total amount/2, where the total amount is the total amount of the amount of insulin bolus initiated by the user. A method for the determination of a corrective value for the system-oriented residual amount of active insulin in the system for measuring a glucose level, and a system for accounting for the residual amount of active insulin are also disclosed.

EFFECT: group of inventions provides for accounting for bolus insulin in such a way that system-oriented IOB (SFIOB) supports only and all corrective insulin as accurately as possible, thus ensuring insulin dosing by the system, which is safe and effective.

14 cl, 6 dwg, 6 ex